Avadomide Plus Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Avadomide Plus Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CC-122-NHL-001): A Multicentre, Dose Escalation and Expansion Phase 1 Study
Lancet Haematol 2020 Aug 03;[EPub Ahead of Print], JM Michot, R Bouabdallah, U Vitolo, JK Doorduijn, G Salles, A Chiappella, PL Zinzani, F Bijou, MJ Kersten, R Sarmiento, S Mosulen, C Mendez, S Uttamsingh, M Pourdehnad, K Hege, T Chen, C Klein, PR Hagner, Z Nikolova, V RibragFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.